Chlamydia trachomatis infection and risk of cervical intraepithelial neoplasia

Sexually Transmitted Infections

Volumn 87, Issue 5, 2011, Pages 372-376

  Lehtinen, Matti ^a   Ault, Kevin A ^b   Lyytikainen, Erika ^c   Dillner, Joakim ^d,e   Garland, Suzanne M ^f,g   Ferris, Daron G ^h   Koutsky, Laura A ⁱ   Sings, Heather L ^j   Lu, Shuang ^j   Haupt, Richard M ^j   Paavonen, Jorma ^k  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OULU   (Finland)

^d LUND UNIVERSITY   (Sweden)

^e KAROLINSKA INSTITUTE   (Sweden)

^f MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h MEDICAL COLLEGE OF GEORGIA   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j MERCK RESEARCH LABORATORIES   (United States)

^k UNIVERSITY OF HELSINKI   (Finland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CANCER RISK; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; COLPOSCOPY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; PAPANICOLAOU TEST; PRIORITY JOURNAL; SEXUAL BEHAVIOR; UTERINE CERVIX CARCINOMA IN SITU; WART VIRUS;

ADOLESCENT; ADULT; CERVICAL INTRAEPITHELIAL NEOPLASIA; CHLAMYDIA INFECTIONS; COITUS; DISEASE PROGRESSION; DNA, VIRAL; EARLY DETECTION OF CANCER; FEMALE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; RISK FACTORS; SEXUAL PARTNERS; UTERINE CERVICAL DYSPLASIA; UTERINE CERVICAL NEOPLASMS; YOUNG ADULT;

EID: 79960699652     PISSN: 13684973     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/sti.2010.044354     Document Type: Article

References (23)

1. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19. (Pubitemid 29406813)
2. Anttila T, Saikku P, Koskela P, et al. Serotypes of Chlamydia trachomatis and risk for development of cervical squamous cell carcinoma. JAMA 2001;285:47-51. (Pubitemid 32042715)
3. Wallin KL, Wiklund F, Luostarinen T, et al. A population-based prospective study of Chlamydia trachomatis infection and cervical carcinoma. Int J Cancer 2002;101:371-4. (Pubitemid 34987525)
4. Quint KD, de Koning MN, Geraets DT, et al. Comprehensive analysis of Human Papillomavirus and Chlamydia trachomatis in in-situ and invasive cervical adenocarcinoma. Gynecol Oncol 2009;114:390-4.
5. Naucler P, Chen H-C, Persson K, et al. Seroprevalence of human papillomavirus and Chlamydia trachomatis and cervical cancer risk: nested case-control study. J Gen Virol 2007;88:814-22. (Pubitemid 46359550)
6. Paavonen J, Purola E. Cytological findings in cervical chlamydial infection. Med Biol 1980;58:174-8. (Pubitemid 11161881)
7. Luostarinen T, Lehtinen M, Bjorge T, et al. Joint effects of different human papillomaviruses and Chlamydia trachomatis infections on risk of squamous cell carcinoma of the cervix uteri. Eur J Cancer 2004;40:1058-65. (Pubitemid 38496264)
8. Arnheim L. Immunological Responses in Genital HPV Infections and Etiology of Cervical Cancer. Stockholm, Sweden: Karolinska Institutet, 2005:1-75. http://diss.kib.ki.se/2005/91-7140-266-7/thesis.pdf (accessed 22 Oct 2009).
9. Agrawal T, Vats V, Wallace L. Role of cervical dendritic cell subsets, co-stimulatory molecules, cytokine secretion profile and beta-estradiol in development of sequalae to Chlamydia trachomatis infection. BMC Reproduct Biol Endocrinol 2008;6:46.
10. Silins I, Ryd W, Strand A, et al. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 2005;116:110-15. (Pubitemid 40827763)
11. Samoff E, Koumans EH, Markowitz LE, et al. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 2005;162:668-75. (Pubitemid 41437366)
12. Velicer C, Zhu X, Vuocolo S, et al. Prevalence and incidence of HPV genital infection in women. Sex Transm Dis 2009;36:696-703.
13. Shew ML, Fortenberry JD, Tu W, et al. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 2006;160:151-6. (Pubitemid 43213859)
14. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356:1928-43.
15. The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007;356:1915-27.
16. International Patent Numbers WO 2003/019143 A2, WO 2006/116276 A2 and WO 2006/116303 A2. http://www.wipo.int/portal/index.html.en. (accessed 5 May 2010).
17. Villa LL, Costa RLR, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 2005;6:271-8.
18. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107:18-27.
19. Li N, Franscheski S, Howell-Jones R, et al. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2011;128:927-35.
20. Cox DR. Regression models and life tables. J R Stat Soc Ser B Methodological 1972;34:187-220.
21. Koutsky LA, Holmes KK, Critchlow CW, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992;327:1272-8.
22. Lehtinen M, Dillner J, Knekt P, et al. Serologically diagnosed infection with human papillomavirus type 16 and risk for subsequent development of cervical carcinoma: nested case-control study. Br Med J 1996;312:537-9. (Pubitemid 26070265)
23. Schiffman M, Clifford G, Buonaguro FM. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009;4:8.